Evaluation Evolving Strategies for Pulmonary Arterial Hypertension: A Focus on Evidence-Based and Cost-Effective Care Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Vallerie V. McLaughlin, MD 5 4 3 2 1 Russell Spjut, PharmD 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Summarize updated recommendations for the diagnosis and treatment of PAH, including risk assessment tools, early diagnosis, referral to specialized centers, and multi-drug regimens 5 4 3 2 1 Evaluate the mechanisms of action and clinical data of current/emerging agents and combination strategies for the personalized treatment of PAH 5 4 3 2 1 Implement updated evidence-based guidelines and best practices into cost-effective managed care policies for optimal PAH outcomes 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with Pulmonary Arterial Hypertension on a monthly basis? 10 or fewer 20 30 40 50 or more Please now rate your ability to use currently available therapies to manage Pulmonary Arterial Hypertension. Excellent Very Good Good Fair Poor Which of the following is recommended at regular follow-up appointments to assess PAH risk? ESC/ERS three-strata model Four-strata model REVEAL 2.0 model SPAHR 3- to 6-parameter model Which of the following is the first once-daily single-tablet combination therapy to be approved for the treatment of PAH? Ambrisentan + selexipag Bosentan + sotatercept Macitentan + tadalafil Sildenafil + epoprostenol Within 1 year of initiating PAH-specific medications, approximately ____ of patients will be hospitalized for all causes and approximately ____ of patients will be hospitalized for PAH causes. 19%, 5% 29%, 15% 39%, 25% 49%, 35% Please rate your confidence now in your ability to design and/or implement managed care policies that consider the latest clinical guidelines and best practices for PAH. Very confident Confident Somewhat confident Not very confident Not at all confident Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Based on my participation in this activity, I anticipate I will more often: (select all that apply) Remain apprised of guideline-directed care strategies for the diagnosis and treatment of patients with PAH Encourage screening for early diagnosis and referral of patients with PAH Reassess drugs for inclusion, exclusion, or change in position in the drug formulary Remain apprised of the mechanisms of action and clinical data of current/emerging agents and combination strategies for PAH Facilitate access to newer therapies and combination strategies by considering formulary designs that reduce patient out-of-pocket expenses Implement systems-based strategies to ensure evidence-based treatment for covered patients with PAH Implement cost-effective and evidence-based managed care policies for patients with PAH Other (fill-in) Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Which of the following best represents the approximate number of patient lives covered by your health plan? 10,000 100,000 250,000 500,000 1 million Other: Which of the following best represents the approximate number of patients affected by migraines covered by your health plan? 5,000 10,000 25,000 50,000 100,000 Other: Previous